Skip to main content
Top
Published in: BMC Immunology 1/2021

Open Access 01-12-2021 | Tuberculosis | Research article

Assessment of CD27 expression on T-cells as a diagnostic and therapeutic tool for patients with smear-negative pulmonary tuberculosis

Authors: Feifan Xu, Haiyun Zhang, Xiaoyan Si, Junlin Chen, Yuhao Chen, Xiaopeng Cui, Yongwei Qin

Published in: BMC Immunology | Issue 1/2021

Login to get access

Abstract

Background

There is a global focus on illness diagnosis in smear-negative and latent tuberculosis infectious populations (SN-TB and LTBI). CD27 has been suggested to play a direct role in active TB. Little is known about smear-negative individuals. Here, we tried to investigate whether it has a role in smear-negative populations. The expression of CD27 and MTB-specific CD27 in CD4+ T cells (“CD27CD4+” and “CD27IFN-γ+CD4+”) was evaluated in MTB-unexposed controls (HC), TB contacts (TB-C) and SN-TB individuals by flow cytometry. The sensitivity, specificity and AUC (area under curve) of “CD27IFN-γ+CD4+” cells to distinguish SN-TBs from HCs and TB-Cs were determined by receiver operating characteristic (ROC) curve analysis. The clinical index was selected from the clinical laboratory and evaluated for correlation with “CD27IFN-γ+CD4+” cells by Spearman statistical analysis.

Results

We observed that the percentages of “CD27IFN-γ+CD4+” cells were significantly increased in the SN-TB group compared with the HC and TB-C groups (AUC was 0.88, sensitivity was 82.14%, specificity was 80.00%, and P < 0.0001). The percentage of “CD27IFN-γ+CD4+” cells was negatively correlated with WBC (white blood cell count) (r = − 0.3019, P = 0.0182) and positively correlated with IgE (immunoglobulin E) (r = 0.2805, P = 0.0362). Furthermore, “CD27IFN-γ+CD4+” cells were significantly decreased, especially in the > 50 years group, after clinical treatment.

Conclusion

The present results demonstrated that the percentage of “CD27IFN-γ+CD4+” cells might be a conceivable molecular indicator in the diagnosis of SN-TB and was influenced by its outcome of therapy.
Appendix
Available only for authorised users
Literature
4.
go back to reference Uruga H, Moriguchi S, Takahashi Y, Ogawa K, Murase R, Hanada S, et al. CLINICAL ANALYSIS OF 115 PULMONARY TUBERCULOSIS PATIENTS WITH SPUTUM SMEAR-NEGATIVE. Kekkaku. 2017;92(3):361–4.PubMed Uruga H, Moriguchi S, Takahashi Y, Ogawa K, Murase R, Hanada S, et al. CLINICAL ANALYSIS OF 115 PULMONARY TUBERCULOSIS PATIENTS WITH SPUTUM SMEAR-NEGATIVE. Kekkaku. 2017;92(3):361–4.PubMed
5.
go back to reference Lombardi G, Di Gregori V, Girometti N, Tadolini M, Bisognin F, Monte PD. Diagnosis of smear-negative tuberculosis is greatly improved by Xpert MTB/RIF. PLoS One. 2017;12(4):e176186.CrossRef Lombardi G, Di Gregori V, Girometti N, Tadolini M, Bisognin F, Monte PD. Diagnosis of smear-negative tuberculosis is greatly improved by Xpert MTB/RIF. PLoS One. 2017;12(4):e176186.CrossRef
8.
go back to reference Sotgiu G, Saderi L, Petruccioli E, Aliberti S, Piana A, Petrone L, et al. QuantiFERON TB gold plus for the diagnosis of tuberculosis: a systematic review and meta-analysis. J Inf Secur. 2019;79(5):444–53. Sotgiu G, Saderi L, Petruccioli E, Aliberti S, Piana A, Petrone L, et al. QuantiFERON TB gold plus for the diagnosis of tuberculosis: a systematic review and meta-analysis. J Inf Secur. 2019;79(5):444–53.
16.
go back to reference Bjerrum S, Broger T, Szekely R, Mitarai S, Opintan JA, Kenu E, et al. Diagnostic accuracy of a novel and rapid Lipoarabinomannan test for diagnosing tuberculosis among people with human immunodeficiency virus. Open Forum Infect Dis. 2020;7(1):z530.CrossRef Bjerrum S, Broger T, Szekely R, Mitarai S, Opintan JA, Kenu E, et al. Diagnostic accuracy of a novel and rapid Lipoarabinomannan test for diagnosing tuberculosis among people with human immunodeficiency virus. Open Forum Infect Dis. 2020;7(1):z530.CrossRef
17.
go back to reference Amelio P, Portevin D, Hella J, Reither K, Kamwela L, Lweno O, et al. HIV Infection Functionally Impairs Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses. J Virol. 2019;93(5):e01728–18. Amelio P, Portevin D, Hella J, Reither K, Kamwela L, Lweno O, et al. HIV Infection Functionally Impairs Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses. J Virol. 2019;93(5):e01728–18.
21.
22.
go back to reference Latorre I, Fernandez-Sanmartin MA, Muriel-Moreno B, Villar-Hernandez R, Vila S, Souza-Galvao ML, et al. Study of CD27 and CCR4 markers on specific CD4(+) T-cells as immune tools for active and latent tuberculosis management. Front Immunol. 2018;9:3094.CrossRef Latorre I, Fernandez-Sanmartin MA, Muriel-Moreno B, Villar-Hernandez R, Vila S, Souza-Galvao ML, et al. Study of CD27 and CCR4 markers on specific CD4(+) T-cells as immune tools for active and latent tuberculosis management. Front Immunol. 2018;9:3094.CrossRef
27.
29.
go back to reference WHO global tuberculosis control report 2010. Summary. Cent Eur J Public Health. 2010;18(4):237. WHO global tuberculosis control report 2010. Summary. Cent Eur J Public Health. 2010;18(4):237.
Metadata
Title
Assessment of CD27 expression on T-cells as a diagnostic and therapeutic tool for patients with smear-negative pulmonary tuberculosis
Authors
Feifan Xu
Haiyun Zhang
Xiaoyan Si
Junlin Chen
Yuhao Chen
Xiaopeng Cui
Yongwei Qin
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2021
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/s12865-021-00430-y

Other articles of this Issue 1/2021

BMC Immunology 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.